We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Lannett (LCI) to Report Q3 Earnings: What's in the Cards?
Read MoreHide Full Article
During Lannett Company, Inc.’s fiscal first-quarter 2019 call, the focus is expected to be on product launches.
Lannett’s shares have slumped 54.4% in the past year compared with the industry’s decline of 13%.
Let’s see how things are shaping up for this announcement.
Factors in Play
Lannett the generic pharmaceutical company launched 17 products in calendar year 2018, which are expected to contribute significantly to net sales in fiscal third-quarter 2019. The company's product launches during the quarter are expected to contribute significantly to sales. Investors’ focus will be on the launch of these products, as stated by the management earlier.
The company intends to realize $66 million in total savings with $33 million of reinvestment. In fact, a portion of these savings is expected to be realized in fiscal third-quarter 2019.
In March 2019, Lannett received approval from the FDA for its abbreviated new drug application (ANDA) for Aspirin and Extended-Release Dipyridamole Capsules, 25 mg/200 mg, the therapeutic equivalent to the reference listed drug, Aggrenox Capsules, 25 mg/200 mg, of Boehringer Ingelheim Pharmaceuticals, Inc. The drug should boost sales for the company in fiscal third quarter 2019.
What Our Model Indicates
Our proven model does not conclusively show that Lannett is likely to beat on earnings in the to-be-reported quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to be able to beat estimates. But that is not the case here, as you will see below.
Earnings ESP: Lannett has an Earnings ESP of 0.00% as both the Zacks Consensus Estimate and the Most Accurate Estimate are pegged at a profit of 62 cents. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company carries a Zacks Rank #2, which increases the predictive power of ESP. However, we need to have a positive Earnings ESP to be confident of an earnings beat.
Note that Sell-rated stocks (Zacks Rank #4 or 5) going into an earnings announcement are best avoided.
Stocks That Warrant a Look
Here are some health-care stocks you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this quarter.
Glaxo SmithKline plc. (GSK - Free Report) has an Earnings ESP of +1.27% and a Zacks Rank #2. The company is scheduled to release first-quarter 2019 results on May 1.
Novo Nordisk A/S (NVO - Free Report) has an Earnings ESP of +0.8% and a Zacks Rank #3. The company is scheduled to release its first quarter 2019 results on May 3.
Will you retire a millionaire?
One out of every six people retires a multimillionaire. Get smart tips you can do today to become one of them in a new Special Report, “7 Things You Can Do Now to Retire a Multimillionaire.”
Image: Bigstock
Lannett (LCI) to Report Q3 Earnings: What's in the Cards?
During Lannett Company, Inc.’s fiscal first-quarter 2019 call, the focus is expected to be on product launches.
Lannett’s shares have slumped 54.4% in the past year compared with the industry’s decline of 13%.
Let’s see how things are shaping up for this announcement.
Factors in Play
Lannett the generic pharmaceutical company launched 17 products in calendar year 2018, which are expected to contribute significantly to net sales in fiscal third-quarter 2019. The company's product launches during the quarter are expected to contribute significantly to sales. Investors’ focus will be on the launch of these products, as stated by the management earlier.
The company intends to realize $66 million in total savings with $33 million of reinvestment. In fact, a portion of these savings is expected to be realized in fiscal third-quarter 2019.
In March 2019, Lannett received approval from the FDA for its abbreviated new drug application (ANDA) for Aspirin and Extended-Release Dipyridamole Capsules, 25 mg/200 mg, the therapeutic equivalent to the reference listed drug, Aggrenox Capsules, 25 mg/200 mg, of Boehringer Ingelheim Pharmaceuticals, Inc. The drug should boost sales for the company in fiscal third quarter 2019.
What Our Model Indicates
Our proven model does not conclusively show that Lannett is likely to beat on earnings in the to-be-reported quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to be able to beat estimates. But that is not the case here, as you will see below.
Earnings ESP: Lannett has an Earnings ESP of 0.00% as both the Zacks Consensus Estimate and the Most Accurate Estimate are pegged at a profit of 62 cents. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Lannett Co Inc Price and EPS Surprise
Lannett Co Inc Price and EPS Surprise | Lannett Co Inc Quote
Zacks Rank: The company carries a Zacks Rank #2, which increases the predictive power of ESP. However, we need to have a positive Earnings ESP to be confident of an earnings beat.
Note that Sell-rated stocks (Zacks Rank #4 or 5) going into an earnings announcement are best avoided.
Stocks That Warrant a Look
Here are some health-care stocks you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this quarter.
Pfizer Inc. (PFE - Free Report) has an Earnings ESP of +0.65% and a Zacks Rank #3. The company is scheduled to release first-quarter 2019 results on Apr 30. You can see the complete list of today’s Zacks #1 Rank stocks here.
Glaxo SmithKline plc. (GSK - Free Report) has an Earnings ESP of +1.27% and a Zacks Rank #2. The company is scheduled to release first-quarter 2019 results on May 1.
Novo Nordisk A/S (NVO - Free Report) has an Earnings ESP of +0.8% and a Zacks Rank #3. The company is scheduled to release its first quarter 2019 results on May 3.
Will you retire a millionaire?
One out of every six people retires a multimillionaire. Get smart tips you can do today to become one of them in a new Special Report, “7 Things You Can Do Now to Retire a Multimillionaire.”
Click to get it free >>